Journal article
Intravitreal Sustained-Release Ganciclovir
Archives of ophthalmology (1960), Vol.110(2), pp.255-258
02/01/1992
DOI: 10.1001/archopht.1992.01080140111037
PMID: 1310588
Abstract
• Current treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome involves frequent intravenous administration of sodium ganciclovir that often results in unacceptable side effects. We have developed devices that release ganciclovir at rates of 2 μg/h and 5 μg/h in vitro. When implanted into the vitreous of rabbit eyes, mean intravitreal ganciclovir levels of 9 mg/L and 16 mg/L were maintained for more than 80 and 42 days, respectively. Devices were well tolerated, with no toxic effects attributable to the polymers used in the devices. This investigation indicates that these devices can maintain therapeutic levels of drug for extended periods and are well tolerated in the rabbit eye. They may prove useful in the clinical management of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Details
- Title: Subtitle
- Intravitreal Sustained-Release Ganciclovir
- Creators
- Thomas J Smith - University of KentuckyP. Andrew PearsonDavid L BlandfordJoel D BrownKenneth A GoinsJack L HollinsElmar T SchmeisserPeter GlavinosLarry B BaldwinPaul Ashton
- Resource Type
- Journal article
- Publication Details
- Archives of ophthalmology (1960), Vol.110(2), pp.255-258
- DOI
- 10.1001/archopht.1992.01080140111037
- PMID
- 1310588
- NLM abbreviation
- Arch Ophthalmol
- ISSN
- 0003-9950
- eISSN
- 1538-3601
- Publisher
- American Medical Association
- Number of pages
- 4
- Language
- English
- Date published
- 02/01/1992
- Academic Unit
- Ophthalmology and Visual Sciences
- Record Identifier
- 9984806500702771
Metrics
6 Record Views